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Anthrax prophylaxis: recent
advances and future directions
E. Diane Williamson* and Edward Hugh Dyson
Defence Science and Technology Laboratory, Porton Down, Salisbury, UK
Anthrax is a serious, potentially fatal disease that can present in four distinct clinical
patterns depending on the route of infection (cutaneous, gastrointestinal, pneumonic,
or injectional); effective strategies for prophylaxis and therapy are therefore required. This
review addresses the complex mechanisms of pathogenesis employed by the bacterium
and describes how, as understanding of these has developed over many years, so too
have current strategies for vaccination and therapy. It covers the clinical and veterinary
use of live attenuated strains of anthrax and the subsequent identification of protein
sub-units for incorporation into vaccines, as well as combinations of protein sub-units
with spore or other components. It also addresses the application of these vaccines
for conventional prophylactic use, as well as post-exposure use in conjunction with
antibiotics. It describes the licensed acellular vaccines AVA and AVP and discusses the
prospects for a next generation of recombinant sub-unit vaccines for anthrax, balancing
the regulatory requirement and current drive for highly defined vaccines, against the risk
of losing the “danger” signals required to induce protective immunity in the vaccinee.
It considers novel approaches to reduce time to immunity by means of combining, for
example, dendritic cell vaccination with conventional approaches and considers current
opportunities for the immunotherapy of anthrax.
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Introduction
Anthrax: The Disease
Anthrax is one of seven globally-neglected diseases, which are both zoonotic and endemic,
according to the WHO (http://www.who.int/zoonoses/neglected_zoonotic_diseases/en/). Anthrax
is primarily a disease of herbivores that become infected through contact with soil contaminated
with persistent bacterial spores. Humans are susceptible to infection through contact with infected
animals or animal products contaminated with bacterial spores. Anthrax is caused by the Gram-
positive sporulating bacterium Bacillus anthracis, as first identified by Robert Koch (Koch, 1876). In
spore form, the bacterium can exist in the environment for centuries (World Health Organization,
Food and Agriculture Organization of the United Nations, World Organization for Animal Health,
2008), surviving desiccation and thermal extremes. Once the bacterial spore gains entry to a
mammalian host, it is taken up by phagocytic cells and transported to the draining lymph nodes
(LNs) where host cells undergo apoptosis and the bacteria germinate into vegetative cells able to
secrete the tri-partite complex of anthrax toxins (reviewed in Abrami et al., 2005).
Depending on the route of exposure, natural anthrax infection in man can take three forms:
cutaneous, gastro-intestinal or most seriously, pneumonic anthrax (Plotkin and Grabenstein,
2008). Recently a fourth form, injectional anthrax, due to the intake of contaminated heroin, has
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been documented (Berger et al., 2014). Following inhalational
exposure to B. anthracis, the spores accumulate in the lung
alveoli and are then engulfed by migratory cells (macrophages,
dendritic cells or neutrophils) which traffic to the mediastinal
and peribronchial LNs. There the bacteria multiply, causing
hemorrhagic mediastinitis, and subsequently spread throughout
the body via the bloodstream causing symptoms of fever,
malaise, fatigue, and mild chest discomfort, progressing to severe
respiratory distress with shock, cyanosis, and death (reviewed
in Guichard et al., 2011). The infection is characterized by a
prodromal phase, which may be asymptomatic, followed by a
sudden onset fulminant phase leading to an abrupt deterioration
into respiratory distress, sepsis, shock and death. If undetected
and untreated, the mortality rate can be very high. In 1979, an
outbreak of anthrax in Sverdlovsk (former USSR), resulted in
an 85% mortality rate in exposed people (Meselson et al., 1994).
However, the prompt and improved intensive care of victims of
the 2001 postal attacks resulted in a mortality of 45% (Jernigan,
2001; Jernigan et al., 2002; Perkins et al., 2002), whilst therapy of
anthrax infection in drug users has been successful (Berger et al.,
2014).
Current and Future Vaccines for Anthrax
There is an ongoing effort to produce better defined vaccines
for anthrax with contemporary formulations and presentations.
This has been based on an evolving understanding of the
complex pathogenesis of anthrax infection and the fact that it
is insufficient to merely reduce the bacteremia with antibiotic
therapy, since beyond a certain tipping point, the toxemia of
anthrax is fatal (Guichard et al., 2011). Vaccines comprising
live attenuated strains of B. anthracis, such as the STI strain,
have been used in the former USSR to vaccinate people and
a veterinary vaccine comprising the Sterne strain is still used
globally to vaccinate cattle (Turnbull, 1991). Licensed human
vaccines for anthrax, comprising filtered supernatants from
bacterial cell cultures, have been in use for the last 60 year
or more (Plotkin and Grabenstein, 2008). These vaccines are
termed Anthrax Vaccine Absorbed (AVA) or Anthrax Vaccine
Precipitated (AVP) in the USA and UK, respectively, since the
vaccine is either absorbed to, or precipitated with, alum salts
(Anthrax Vaccine Adsorbed, 1965; Hepburn et al., 2007; Wright
et al., 2010). The AVA and AVP vaccines, made by batch culture
of pX01+/pX02− B. anthracis strains, comprise predominantly
PA with trace quantities of various other bacterial derived
components. AVA contains traces of LF but is virtually free of
EF, while AVP contains some LF and traces of EF. However, due
to the method of production, the relative concentrations of these
proteins in consecutive batches can vary and in the UK, AVP is
produced within biocontainment.
To achieve a more defined vaccine, the recombinant
expression of PA and/or LF has been pursued and a number
of candidate rPA vaccines are currently in development and
in clinical trials for safety (Plotkin and Grabenstein, 2008).
Additionally formulations comprising spore coat proteins
in combination with PA have been proposed (Brossier
et al., 2002). In subsequent sections, the virulence and
pathogenesis of B. anthracis is reviewed, in order to place
in context the effort toward next generation vaccines for
anthrax.
Virulence Factors from B. Anthracis
B. anthracis expresses a number of virulence factors. The poly-D-
glutamic acid (PGA) capsule, encoded by the pXO2 plasmid, is
a major virulence determinant; it ensures environmental survival
of the spore and in vivo disguises the bacterium from immune
surveillance and protects it from phagocytosis (Jang et al., 2011).
PGA is weakly immunogenic and in vitro the capsule can
activate caspase1 and induce IL1β release from THP1 and human
monocyte- derived dendritic cells. PGAwas observed to associate
with LT in the blood of infected animals (Ezzell et al., 2009) and
further research showed that PGA enhanced the cytotoxicity of
LT for murine cells in vitro and the toxemia of terminal anthrax
in vivo (Jang et al., 2011). During infection, PGA may also
target the bacteria to enter the vascular endothelial cell (VEC)
wall, from where they can secrete toxins (Piris-Gimenez et al.,
2009).
An S-layer protein, BslA, is encoded by the pXO1 plasmid and
is another virulence factor; it promotes adhesion to mammalian
cells including VECs. A pore-forming toxin, anthrolysin, is also
secreted by B. anthracis and activates the Toll-like receptor 4
(TLR4) on macropahges, inducing apoptosis. Anthrolysin acts
in concert with EF and LF to enhance toxemia (Guichard et al.,
2011).
B. anthracis also secretes proteases which contribute to
its virulence by reducing cellular barrier function thereby
promoting vascular leakage, and also by triggering the host
coagulation cascade. In this context, DIC and profound
thrombocytopenia appear to be pre-mortem signs in injectional
anthrax—possibly markers of the tipping point (Berger et al.,
2014).
All of these virulence factors contribute to pathogenesis, and
may interact with the toxins secreted by the bacterium. However,
although the bacteremia can be treated with antibiotics, if the
toxemia progresses beyond a tipping point, it will ultimately
prove fatal.
Pathogenesis of Anthrax Infection
During infection, B. anthracis spores germinate and release three
proteins, termed Protective Antigen (PA), Lethal Factor (LF), and
Edema Factor (EF; Smith, 2002). Both LF and EF are enzymes:
LF is a zinc metalloprotease that cleaves the N-terminus of
several mitogen-activated protein kinase kinases (MAPKKs) or
MAP/ERK kinases (MEKs) and EF is an adenylate cyclase. PA is
the cell-binding component of a binary complex with LF (to form
lethal toxin, LT) or with EF (to form edema toxin, ET). LT and ET
are potent toxins (Abrami et al., 2005).
Much is now known about the process of host cell-binding
by PA prior to endocytosis of either of these toxic complexes
(Abrami et al., 2005). The full-length (83 kDa) PA binds to one
or more host cell receptors: Capillary Morphogenesis factor 2
(CMG2), Trans-endothelial membrane receptor 8 (TEM8), or
β1-integrin (Martchenko et al., 2010). It then undergoes furin
cleavage to release a 20 kDa N-terminal fragment, leaving a
63 kDa truncated protein (PA63) which is subject to a structural
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rearrangement with heptamerisation, so that domain 4 is in
contact with the host cell receptor. In the process, binding sites
for either three molecules of LF or EF are exposed on units of the
PA heptamer (a maximum of nine toxic complexes are generated
per PA 7mer) and the latter associates with lipid rafts, mediated
by the lipoprotein-receptor-related protein 6 (LRP6; Wei et al.,
2006). Subsequently, the toxic complex undergoes clathrin-
mediated endocytosis (Abrami et al., 2010) and enters early
endosomes where it is incorporated into intraluminal vesicles
(Figure 1). Acidification of the endosome allows insertion of the
PA7mer into the membrane of the intraluminal vesicles as well
as the unfolding and release of LF and EF through the channel
of the PA7mer, into the lumen of the vesicle. Subsequently, both
LF and EF undergo microtubular transport through the lumen
of the vesicles to late perinuclear endosomes. Here, the vesicles
can undergo back fusion with the limiting membrane so that
LF is released into the perinuclear cytoplasm (Liu et al., 2003;
Abrami et al., 2006; van der Goot and Young, 2009) where it
cleaves MAPKKs to disrupt phosphorylation and transcription
in the nucleus, ultimately preventing protein synthesis and
causing cell death. EF, a calcium and calmodulin-dependent
adenylate cyclase, remains bound to late perinuclear endosomes,
where it causes a rapid increase in perinuclear cAMP resulting
in cellular, tissue and ultimately organ oedema (Tang and Guo,
2009).
Early 
endosome
Phagolysosome
Late 
endosome
EF
LF
LT/ET
FIGURE 1 | Delivery of LF and EF into the host cell. PA 83 binds to cell
surface receptors and is subsequently cleaved and oligomerises to form a
heptamer (PA7mer). LF and EF can bind to the PA7mer to form lethal toxin (LT)
or edema toxin (ET) which associate with lipid rafts. These complexes are
endocytosed (in clathrin-coated pits, facilitated by LRP6) and enter early
endosomes. Subsequently, LT/ET are conveyed in vesicles to late perinuclear
endosomes. The PA7mer forms a pore in the vesicle luminal wall, releasing EF
to the membrane and LF to the cytosol. EF creates a gradient of cAMP
emanating from the nucleus to the cell wall, whilst LF cleaves the MAP/ERK
kinase (MEK) substrate to inhibit nuclear protein synthesis. Glossary: MAPKKs,
mitogen-activated protein kinase kinases; ERKK, extracellular-signal-regulated
kinases; MEK, MAP/ERK kinases.
Evasion and Antagonism of the Host Immune
Response
It is hypothesized that LF and EF have evolved to use this cellular
entry pathway to evade exposure to lysosomal proteases and the
host immune response (van der Goot and Young, 2009). Both LF
and EF suppress host cytokine secretion (Tournier et al., 2005)
and weaken vascular endothelial barriers by downregulating
vascular cadherin, important in cell-cell adhesion (Guichard
et al., 2010). This effect is thought to contribute to the vascular
leakage typical of systemic anthrax (Moayeri and Leppla, 2004).
ET appears to have co-opted a host signaling pathway to
facilitate the transport of bacteria from the lung to LNs. It is
hypothesized that ET mimics the anti-inflammatory action of
G-protein coupled receptors (GPCRs) to induce macrophage
migration, ultimately delaying apoptosis and increasing the
delivery of bacteria by macrophages to the LNs (Abrami et al.,
2005, 2006; Tang and Guo, 2009; Guichard et al., 2011).
Intracellularly, EF and LF appear to act synergistically to delay
apoptosis. The pore-forming toxin anthrolysin binds TLR4
receptors, providing conflicting signals to induce apoptosis (via
PKR) or to inhibit via MEK. However, by cleaving MEK’s, LF
blocks this inhibitory and protective signal, shifting the balance
of TLR4 signaling toward apoptosis. EF counters this effect by
signaling through the PKA and CREB pathways, protecting the
macrophage during its migration to the LN where apoptosis
occurs to release bacteria and spores (Figure 2), although this
TRIF
TLR4
Anthrolysin
PKR
Promotes      
apoptosis
MEK
Inhibits 
apoptosis
LF cleaves
Promotes 
apoptosis
EF
PKA
CREB
Delays  apoptosis
FIGURE 2 | Opposing effects of anthrolysin, LF and EF on host cell
apoptosis. Anthrolysin secreted by B. anthracis binds surface TLR4 receptors
with downstream signaling through either TRIF and PKR to promote
apoptosis, or through MEK to inhibit apoptosis; the latter inhibitory effect is
opposed by LF cleaving MEK, thus promoting apoptosis. EF signals through
the PKA and CREB pathway which has benefit in delaying apoptosis until the
phagocytic host cell reaches the lymph node, an optimal niche for germination
with further toxin release. Glossary: PKR, protein kinase regulated by RNA;
PKA protein kinase A; CREB, cAMP response-element-binding protein; TRIF,
TIR-domain-containing adapter-inducing interferon-β.
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effect is not definitive and in some models ET has been proposed
to inhibit macrophage migration (Guichard et al., 2011).
Observed differences in the sensitivity of rodents to the effects
of anthrax toxins in vivo have led to further study of Nlrp1b,
a component of the inflammasome pathway which mediates
cell death in LT-sensitive macrophages through a rapid non-
apoptotic mechanism termed pyroptosis (Guichard et al., 2011).
In vivo susceptibility of LT-sensitive rodents did not however
correlate with macrophage sensitivity in vitro, suggesting that
premature killing of macrophages and inflammasone activation
in Nlrp1b-sensitive strains may lead to IL1-mediated neutrophil
influx and bacterial killing, thus reducing bacterial dissemination
and promoting survival. However, human and non-human
primate macrophages have been shown to be resistant to LT
pyroptosis (Ribot et al., 2006), undergoing the slower process
of apoptosis, and so the relevance of the Nlrp1b inflammasome
pathway in anthrax infection in humans is uncertain.
There have been many reports, some conflicting, on the effect
of anthrax toxins on host cell cytokines and the induction of
immune signals and bactericidal factors. Overall, LF and EF both
suppress host cell cytokine signaling and cell surface activation
markers to achieve suppression of the host immune response
(Moayeri and Leppla, 2004; Tournier et al., 2009).
End-stage Toxemia
The current paradigm is that in fulminant anthrax infection,
anthrax toxins kill the host by direct effects on the cardiovascular
system (Guichard et al., 2011). ET and LT decrease the vascular
barrier integrity of VECs; ET and LT cause cardiovascular
dysfunction with ET causing hypotension by increasing vascular
permeability and vasodilation, whilst LT acts directly on the
heart to compromise structure and performance. Overall, the
combined effects of the toxins is to break down the barrier
between the vasculature and the tissues, causing systemic
effects with fatal outcome, leading to disseminated intravascular
coagulation (DIC), profound thrombocytopenia, respiratory
shock and cardiac failure (Berger et al., 2014). There may also
be CNS involvement as bacteria are disseminated through highly
vascularized membranes such as the meninges which can lead to
cerebral hemorrhage.
What Is Required to Prevent Anthrax Toxemia?
It is assumed that vaccination with PA-containing vaccines
or immunotherapy with antibody to PA, work to prevent PA
binding to host cell receptors and the downstream toxic sequelae.
PA has been co-crystallized with CMG2 and the binding of PA
to this receptor and to TEM8 has been characterized extensively
(van der Goot and Young, 2009). Evidence that preventing
PA binding to cell surface receptors is sufficient to inhibit
cytotoxicity, without needing to prevent internalization of the
PA7mer comes from microelectrode array studies (Tournier et al.,
2009). A biocompatible microelectrode array, coated with J774
mouse macrophages, has been used to investigate the cellular
effects of PA binding (Trouillon et al., 2012). It was found
that exposing macrophages to 20µg.ml−1 of rPA activated
the inducible isoform of NO synthase (iNOS), thus increasing
the extracellular concentration of NO and nitrite, in a dose-
and time-dependent manner. The induction of iNOS in J774
cells could be detected with rPA concentrations as low as
10 ng.ml−1 if the cells were pre-treated with the pro-oxidant
azidothymidine. Interestingly the binding of domain 4 of rPA
(PA4) alone to cells, involving an intracellular cascade through
the ERK 1/2 and the PI-3/Akt kinase pathways, was as effective in
triggering this response. Inhibition of either intracellular pathway
abrogated the NO response. Furthermore, pre-treatment of the
cells with antibody to PA or to PA4 also abrogated this effect,
demonstrating that it was specific. Thus, high affinity antibody
specific for PA, administered as an immunotherapy (Albrecht
et al., 2007; Riddle et al., 2011) or circulating antibody which has
been induced by vaccination with PA-containing vaccines, should
block PA binding to the CMG2 or TEM8 receptors. A recent
study has shown that monocytes from human subjects who had
recovered from cutaneous anthrax, had reduced expression of the
TEM8 receptor, despite enhanced IFNγ recall responses to PA by
their PBMCs (Ingram et al., 2013).
This is not to say, of course that a cell-mediated immune
response is not required for protection against anthrax infection.
Extensive studies with PA-containing vaccines in animals and
in man have shown that PA induces a strong and specific Th
(CD4+)- mediated response in vaccinees, whose polarization
will be strongly influenced by the formulation, particularly the
adjuvants used (Flick-Smith et al., 2002a; Boyaka et al., 2003;
Bielinska et al., 2007; Park et al., 2008; Ingram et al., 2013).
This cellular memory response sustains titres of PA-specific
antibodies.
Structure: Function Activity in PA
The crystal structure of the 83 kDa PA protein has been solved
(Petosa et al., 1997) and shows that PA comprises four distinct
domains, with domain 1a being removed by furin cleavage at
the host cell receptor surface. Subsequently PA undergoes a
conformational rearrangement to form PA7mer and LF/EF bind
sites located in domain 1b and the adjacent domain 3. Upon
activation of an acidic switch, a long loop from each of the
seven PA monomers rearranges into a β-hairpin forming a 14-
stranded transmembrane porin-like β barrel, through which LF
(and probably EF) are translocated in unfolded form into the
host cell where they re-fold (reviewed in Abrami et al., 2013).
This rearrangement means that domain 4 is the principal contact
with the host cell receptor. A study to determine the relative
immunogenicity of recombinant proteins representing these
domains of PA was undertaken in a murine model of anthrax
infection (Flick-Smith et al., 2002b). Whilst all the domains were
immunogenic, only immunization with domain 4 protected mice
against challenge with B. anthracis, and to the same level as that
provided by intact PA. PA domain 4 contains the host cell binding
region (Little et al., 1996) and is critical for the function of PA as
a pore-forming toxin (Lacy et al., 2004).
Structure: Function Activity in LF
LF is a protein of similar mass to PA, which also comprises
four distinct domains: an N-terminal PA-binding domain 1;
domain 2 involved in binding to residues in MEK substrates
distant form the cleavage site; a small domain 3 involved in
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binding to the cleavage site of MEK substrates and a catalytic
domain 4. Domains 3 and 4 are together required for binding
MEK substrates, to achieve cleavage (Ascough et al., 2012). As
for PA, the domains of LF have been individually expressed as
recombinant proteins and used to probe sera from volunteers
immunized with the AVP vaccine for reactivity, whilst also being
used to determine their efficacy as immunogens in mice (Baillie
et al., 2010). Four of four vaccinated subjects recognized both
PA and LF by Western blotting and all subjects had a memory
response for LF, whilst two of four had a recall response to PA.
Mice immunized with either LF domain 1, or intact LF were fully
protected against bacterial challenge. Efficacy against a doubled
challenge level was further enhanced by using a fusion of LF
domain1 to PA domain 4 to immunize mice, indicating synergy
between these individual protein domains (Baillie et al., 2010).
Structure: Function Activity in EF
Like PA and LF, EF is a protein of mass around 80 kDa and
is a highly active calmodulin-dependent adenylate cyclase. It
comprises three domains: an N-terminal binding domain 1; a
catalytic domain consisting of two sub-domains which enclose
the catalytic site at their interface; and a C-terminal helical
domain (Liu et al., 2003). In the absence of host calmodulin, the
helical domain associates with the catalytic domain to block its
activity, but this protection is lost on exposure to host calmodulin
which binds to the N-terminal portion of the helical domain, thus
exposing the catalytic domain. Because of its localisation in vivo
to perinuclear endosomes, EF causes a gradient in cAMP from
the nucleus to the plasma membrane.
What Does the Immune Response to Natural
Exposure Tell Us?
Natural exposure to B. anthracis, for example, by cutaneous
infection, has been found to induce long-lived CD4+ Th1—
mediated cellular memory to both PA and LF. The duration
of infection correlated significantly with the development of a
cellular recall response to PA, whilst the response to LF was
focused on domain 4, with convalescent individuals having a
significantly enhanced recall response to domain 4, compared
with subjects previously vaccinated with AVP (Ingram et al.,
2010). Epitope mapping of the CD4 response to domain 4
showed a heterogeneous response across the domain 4 sequence,
but with one epitope which overlapped the catalytic center
of the metalloprotease being recognized predominantly by
convalescent subjects and only rarely by vaccinees. This epitope
was strongly HLA-DR15-resitricted. This suggests that infection
has unveiled cryptic epitopes, not commonly recognized in the
response to vaccination. Subsequently, a detailed study of LF
epitopes determined that immunodominant T-cell epitopes in
LF exist predominantly in domains 2 and 4 and are composed
of residues critical for efficient catalytic activities and substrate
cleavage. An immunodominant epitope in domain II was
strongly recognized by multiple diverse HLA types (Ascough
et al., 2014).
The observation that the T-cell recall response of convalescent
individuals was predominantly focused on the LF domains
responsible for MAPKKs cleavage in the host cell is significant,
since the MAPK pathways are critical in the control of T-cell
activation and differentiation. Thus a host response against these
epitopes is necessary for defense. LT is capable of inhibiting JNK,
ERK and p38-mediated T-cell proliferation and associated Th1
cytokine secretion. ET is able to act synergistically with LT on
the MAPK pathways to suppress T-cell chemotaxis and block
the migration of naïve and effector T-cells to infected tissues.
Together with the ability of EF to increase intracellular cAMP, the
combined effect of these synergistic toxins would be to polarize
naïve CD4+T-cells to an anti-inflammatory Th2 response, which
is not optimal to counter anthrax infection.
Clinical Prospects
In the currently licensed vaccines, AVA and AVP, PA is the
predominant immunogen; in addition, AVA contains traces of
LF but is virtually free of EF, while AVP contains some LF
and traces of EF. Non-clinical data from the use of these
vaccines experimentally would suggest that both AVA and AVP
are efficacious in protecting animals, when given before and,
within a defined time-frame, following exposure. Recent reports
from substantial and systematic studies in non-human primates
have identified serological correlates of protection which predict
vaccine efficacy in man (Fay et al., 2012; Chen et al., 2014;
Schiffer et al., 2015). In clinical use however, the AVA and AVP
formulations can be reactogenic and current efforts are aimed
at rationalizing the clinical dosing regimen to reduce dosing
frequency (Anthrax ACIP and Vaccine Recommendations, 2001;
Shepard et al., 2002; Wright et al., 2014) whilst enhancing
immunogenicity by the inclusion of CpG, for example in the AVA
formulation, as NuThrax (Ionin et al., 2013; Minang et al., 2014).
The reported reactogenicity has been attributed to extraneous
components in these formulations, and principally the presence
of LF/EF, leading to efforts to develop a next generation anthrax
vaccine as a more defined recombinant vaccine which can be
manufactured more readily, without the need for high levels of
biocontainment (Friedlander and Little, 2009).
The comprehensive understanding which has developed of
the pathogenesis of anthrax infection provides a rationale for
PA as the single required pivotal component of anthrax vaccines
for prophylactic use. If the initial host cell entry event can
blocked by adaptive immunity (vaccination) or passive immunity
(immunotherapy) then the downstream bacteraemia and toxicity
can be prevented.
Several recombinant vaccines in which PA is the single
active component are in development [http://www.fda.gov/
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/
BloodVaccinesandOtherBiologics/VaccinesandRelatedBiological
ProductsAdvisoryCommittee/UCM232400.pdf; http://www.hhs.
gov/news/press/2015pres/03/20150323a.html; (Williamson et al.,
2005; Friedlander and Little, 2009)]. These have the advantage of
being defined, highly purified formulations which are enriched
for PA. Additionally they can be formulated appropriately with
current effective adjuvants e.g., TLR agonists and presented as
liquid or lyophilised formulations, to maximize immunogenicity
and efficacy.
Whilst there is a requirement for vaccines and therapies to
be highly defined to meet regulatory requirements, this bears
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the risk that some of the apparently extraneous components in
older, less defined preparations may contribute to protection.
This is the context with anthrax vaccination, where in the future
there may be the option of transferring from existing licensed
products such as AVA/AVP, to a recombinant licensed vaccine,
such as rPA. By the judicious use of synthetic adjuvants or
excipients that engage TLR receptors, it is hoped that the best
of both worlds can be achieved i.e., highly defined, recombinant
active components which nevertheless deliver sufficient “danger”
signals to the human immune system to induce a protective
response. A precedent for this has been reported with the
introduction of the safer, but less immunogenic acellular pertussis
vaccine for whooping cough, where it is proposed that the safer,
recombinant acellular vaccine formulated in alum could also be
supplemented with CpG as a TLR agonist to provide the danger
signal (Ross et al., 2013). In this formulation, alum would drive
an IL1β/IL17 response, whilst CpG would drive an IFNy+ Th1
response; both Th1 and Th17 signaling are required for bacterial
clearance and protective immunity. Similar considerations apply
to the identification of candidate vaccines for tuberculosis which
may provide more efficacious alternatives to BCG (Blankley et al.,
2014).
Post-exposure Vaccination or Immunotherapy of
Anthrax
It has been estimated that PA may be detected in blood at
approximately 24–48 h after an individual has been exposed to B.
anthracis spores (Malkevich et al., 2014). If PA is present, then it
could be assumed that LF and EF will also be secreted and LF has
been detected in rhesus macaque serum at 36 h post-infection,
rising to high levels >1000 ng/ml by 120 h p.i. (Boyer et al., 2007,
2009, 2015). The therapy that is initiated will therefore depend on
the period that has elapsed after suspected or actual exposure to
B. anthracis.
In this context, AVA or AVP may be offered to an individual
together with 60 days of antibiotic therapy (Chen et al., 2014).
Following the anthrax letters in 2001, there was evidence of
widespread non-compliance with the 60-day antibiotic regimen
(Schiffer et al., 2015). In the future it may be possible to shorten
the antibiotic course post-exposure, once there is sufficient
experimental evidence that the combination with vaccination is
efficacious. Non-clinical evidence indicates that an rPA vaccine
administered in two rapid doses (days 0 and 7) under antibiotic
cover (starting 6–12 h post-exposure to aerosolised B. anthracis
spores) in a rabbit model of anthrax infection, provided full
protection with no bacteremia in recipients (Leffel et al., 2012). By
comparison, only 56% of rabbits that received antibiotics without
rPA vaccine survived exposure to B. anthracis and 50% were
bacteremic. However, this study also showed that when the rPA
vaccine dose was reduced by 90%, whilst the levofloxacin dosage
was maintained, survival was reduced to 89 and 11% of animals
were bacteremic.
In 2012, a new immunotherapeutic, Raxibacumab
from Glaxo-Smith Kline, was licensed by the FDA for
the treatment of inhalational anthrax (http://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm).
Raxibacumab is a humanized monoclonal antibody with
specificity for PA. In a rabbit model of anthrax infection, 82%
of animals treated with antibiotics and Raxibacumab survived
exposure to anthrax, compared with 65% of animals receiving
antibiotic treatment alone. A Biologics Licence application for
another anti-PA monoclonal, Anthim from Elusys, has been filed
this year.
Monoclonal antibodies for LF and PA have been evaluated in
combination in a murine model of anthrax infection (Albrecht
et al., 2007). The combinedMabs were administered 2.5 h prior to
challenge with B. anthracis and each independently provided full
protection, whilst also allowing recipient mice to generate toxin-
neutralizing antibody titres de novo in response to the challenge,
so that they were protected against a second challenge 21 days
later, without any additional treatment. Similarly a monoclonal
antibody to LF has been evaluated in a rat model of anthrax (Lim
et al., 2005).
Some have recommended that a cocktail of Mabs to all
the anthrax toxins plus the capsule, should be available for
post-exposure therapy in order to target all the stages in the
infection process (Chen et al., 2011; Ding et al., 2013) and that
combinations of Mabs may provide enhanced protection (Pohl
et al., 2013). Work on these combination approaches indicated
that targeting several epitopes on LF is required for effective toxin
neutralization (Pohl et al., 2013).
However, passive immunotherapy, although useful in a
post-exposure context under antibiotic cover, will give only
limited protection, dependent on the half-life of the antibody.
A novel combination of immunization with dendritic cells
(Mohamadzadeh et al., 2009) which had been pre-pulsed with
rPA + CpG, together with conventional immunization with rPA
in alum, served to significantly shorten time to immunity in a
murine model and also to reduce significantly the bacterial load
post-exposure (Thompson et al., 2014).
Concluding Comments
Significant progress has been made in the last 60 years, from
first discovery of the toxins secreted by the bacterium, to the
detailed understanding we have today of their toxigenic effects.
This in turn allows for new approaches to the prophylaxis and
therapy of anthrax. Much effort and resource has been invested
in the prophylaxis and therapy, following recognition of anthrax
as a contemporary biothreat subsequent to the anthrax letters
attack in the US in 2001, as well as by sporadic cases of anthrax
in heroin users in Europe. This has led in the past few years
to the licensing of new immunotherapies and the progression
through clinical trials of next generation vaccines. Together, these
developments provide hope for accelerated progress in the future
toward comprehensive prophylaxes and therapies for anthrax,
which can be made consistently by recombinant expression, at
the required scale and time, without the need for culture of the
pathogen in biocontainment. However, in the drive for highly
defined next generation vaccines, the need to provide sufficient,
controlled “danger” signals in the formulation to simulate the
natural response to an infection in the vaccinee, should not
be forgotten. In the twenty-first century, this requirement is
facilitated by the increasing availability of synthetic versions of
TLR ligands.
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